Latest News for SHIEF
Shield Therapeutics plc (SHIEF) Discusses Strategic Acquisition of Full U.S. Commercial Control of ACCRUFeR Transcript
Cavendish has reiterated its buy rating on Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) following the pharmaceutical company's agreement to take full commercial control of its main United States (US) product from Viatris. The broker kept its target price at 23 pence, implying potential upside of 318% from current share price of about 5.5 pence.
Shares in Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) rose 11% to 4.89p on Thursday after the pharmaceutical company reported sharply narrower half-year losses and reaffirmed its aim of reaching operating profitability in 2026. Peel Hunt reiterated its 'buy' rating and 15p price target, describing the first-half results as in line and the business as on track for profitability this year.
Shield Therapeutics plc (SHIEF) Q2 2026 Sales/Trading Call Transcript
Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) told investors it remained profitable in the first half as a China milestone payment and higher royalties lifted revenue 41% to $30.4 million, with the company reiterating that it is on track for profitability in 2026. The $7.9 million development payment from partner ASK offset softer second-quarter trading.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for SHIEF.
Senate Trading
No Senate trades found for SHIEF.
U.S. House Trading
No House trades found for SHIEF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.